Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.64
+0.31 (+1.76%)
Streaming Delayed Price
Updated: 3:04 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
January 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
December 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
December 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
MarketBeat Week in Review – 11/27 - 12/1
December 02, 2023
Stocks closed the week at or near yearly highs after subdued inflation numbers suggest the Federal Reserve will continue to pause on raising rates
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
November 28, 2023
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
Via
MarketBeat
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
November 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
November 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
November 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
November 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
October 25, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
October 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Changes to Executive Management Team
September 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Settles Price Fixing Charges With U.S. DOJ
August 21, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
July 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
July 05, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
June 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.